Tallia Oyando reveals she turned to GLP-1 for weight loss because of PMOS
By Valerian Khakayi, September 17, 2026Media personality Talia Oyando has opened up about living with Polyendocrine Metabolic Ovarian Syndrome (PMOS), explaining how the condition affected her weight and eventually led her to turn to GLP-1 medication.
Oyando shared her experience during PMOS Awareness Month, revealing that she began experiencing symptoms in her early 20s, which continued into her 30s and became increasingly difficult to manage.
“September is PMOS Awareness Month (Polyendocrine Metabolic Ovarian Syndrome), and I get a lot of people who are asking, ‘Why did I get on GLP-1?’ It is because of PMOS that I started experiencing symptoms in my early 20s through to my 30s, and it got really bad and unbearable, and that is why I got into GLP-1,” Oyando said.
PMOS-related weight gain
The media personality said one of the challenges she experienced was persistent weight gain despite making efforts to maintain a healthy lifestyle.
“The weight gain was increasing, and I was on the gym, on my diet, eating well and working out, but even as much as I was doing that, I kept adding weight,” she said.
Her remarks explain why she decided to explore GLP-1 medication after conventional efforts, including exercising and maintaining her diet, did not stop the weight gain she was experiencing.
Oyando said she has since learnt to manage the condition and its symptoms better, although she continues to live with PMOS.
“I have lived with it well. I still live with it but am managing my symptoms and distress better now. I found something that’s worked for me,”she added.
Oyando also addressed people who may perceive the use of GLP-1 medication for weight management as an easy solution.
“I know a lot of people may think it’s a shortcut, but living with pain every day was not on my bingo card,” Oyando stated.
What is GLP-1?
GLP-1 stands for glucagon-like peptide-1, a naturally occurring hormone that helps regulate blood sugar, appetite and food intake.
GLP-1 receptor agonists are medicines that mimic the effects of this hormone. Some are approved for treating type 2 diabetes, while certain medicines in this class are also approved for chronic weight management.
The medicines can help reduce appetite and increase feelings of fullness, making it easier for some people to reduce their food intake. They are generally prescribed alongside lifestyle changes and are not suitable for everyone.
What is PMOS?
Polyendocrine Metabolic Ovarian Syndrome (PMOS) is a term used to describe a combination of reproductive, metabolic and endocrine disturbances affecting women.
Oyando’s account highlights how she experienced the condition, particularly its impact on her weight. She said the weight gain continued despite exercising, eating well and following a diet, eventually becoming one of the reasons she sought another approach.
Her experience also comes as she uses PMOS Awareness Month to create awareness about the condition and explain her decision to use GLP-1 medication.
For Oyando, the decision was not simply about losing weight but came after years of dealing with symptoms and persistent weight gain that she said had become difficult to manage.